Display options
Cite
Rangasamy SB, Dasarathi S, Nutakki A, et al. Stimulation of Dopamine Production by Sodium Benzoate, a Metabolite of Cinnamon and a Food Additive. J Alzheimers Dis Rep. 2021;5(1):295-310doi: 10.3233/ADR-210001.
Rangasamy, S. B., Dasarathi, S., Nutakki, A., Mukherjee, S., Nellivalasa, R., & Pahan, K. (2021). Stimulation of Dopamine Production by Sodium Benzoate, a Metabolite of Cinnamon and a Food Additive. Journal of Alzheimer's disease reports, 5(1), 295-310. https://doi.org/10.3233/ADR-210001
Rangasamy, Suresh B, et al. "Stimulation of Dopamine Production by Sodium Benzoate, a Metabolite of Cinnamon and a Food Additive." Journal of Alzheimer's disease reports vol. 5,1 (2021): 295-310. doi: https://doi.org/10.3233/ADR-210001
Rangasamy SB, Dasarathi S, Nutakki A, Mukherjee S, Nellivalasa R, Pahan K. Stimulation of Dopamine Production by Sodium Benzoate, a Metabolite of Cinnamon and a Food Additive. J Alzheimers Dis Rep. 2021 Apr 23;5(1):295-310. doi: 10.3233/ADR-210001. PMID: 34113786; PMCID: PMC8150256.
Copy Download .nbib Format: NLM
Share it on

J Alzheimers Dis Rep. 2021 Apr 23;5(1):295-310. doi: 10.3233/ADR-210001.

Stimulation of Dopamine Production by Sodium Benzoate, a Metabolite of Cinnamon and a Food Additive.

Journal of Alzheimer's disease reports

Suresh B Rangasamy, Sridevi Dasarathi, Aparna Nutakki, Shreya Mukherjee, Rohith Nellivalasa, Kalipada Pahan

Affiliations

  1. Division of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, IL, USA.
  2. Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.

PMID: 34113786 PMCID: PMC8150256 DOI: 10.3233/ADR-210001

Abstract

BACKGROUND: Parkinson's disease (PD) is one of the most important neurodegenerative disorders in human in which recovery of functions could be achieved by improving the survival and function of residual dopaminergic neurons in the substantia nigra pars compacta. Tyrosine hydroxylase (TH) is the rate-limiting enzyme in the dopamine (DA) biosynthesis pathway.

OBJECTIVE: Earlier our laboratory has shown that sodium benzoate (NaB), a metabolite of cinnamon and an FDA-approved drug against urea cycle disorders and glycine encephalopathy, increases neuroprotective molecules and protects dopaminergic neurons in a mouse model of PD. Here, we examined whether NaB could stimulate the production of DA in dopaminergic neurons.

METHODS: We employed PCR, real-time PCR, western blot, immunostaining, and HPLC to study the signature function of dopaminergic neurons. Locomotor functions were monitored in mice by open-field.

RESULTS: NaB increased the mRNA and protein expression of TH to produce DA in mouse MN9D dopaminergic neuronal cells. Accordingly, oral feeding of NaB increased the expression of TH in the nigra, upregulated striatal DA, and improved locomotor activities in striatum of normal C57/BL6 and aged A53T-

CONCLUSION: These results indicate a new function of NaB in which it may be beneficial in PD via stimulation of DA production from residual dopaminergic neurons.

© 2021 – The authors. Published by IOS Press.

Keywords: A53T; CREB; dopamine; sodium benzoate; striatum; substantia nigra pars compacta; tyrosine hydroxylase

Conflict of interest statement

The authors have no conflict of interest to report.

References

  1. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8968-73 - PubMed
  2. J Neuroimmune Pharmacol. 2012 Jun;7(2):424-35 - PubMed
  3. Nat Med. 2004 Jul;10 Suppl:S58-62 - PubMed
  4. J Immunol. 2009 Nov 1;183(9):5917-27 - PubMed
  5. Neurochem Res. 2015 Nov;40(11):2333-47 - PubMed
  6. N Engl J Med. 1998 Oct 8;339(15):1044-53 - PubMed
  7. J Neuroimmune Pharmacol. 2016 Dec;11(4):693-707 - PubMed
  8. Ann Neurol. 2004 Oct;56(4):532-9 - PubMed
  9. J Biol Chem. 2003 Jun 20;278(25):22424-31 - PubMed
  10. Lancet. 1990 Apr 21;335(8695):948-52 - PubMed
  11. J Neuroimmune Pharmacol. 2013 Jun;8(3):739-55 - PubMed
  12. Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9435-40 - PubMed
  13. Nat Rev Neurosci. 2017 Jan 20;18(2):101-113 - PubMed
  14. J Neuroimmune Pharmacol. 2014 Sep;9(4):569-81 - PubMed
  15. J Neuroimmune Pharmacol. 2014 Mar;9(2):218-32 - PubMed
  16. J Biol Chem. 2006 May 26;281(21):14971-80 - PubMed
  17. J Immunol. 2016 Oct 15;197(8):3099-3110 - PubMed
  18. JCI Insight. 2020 May 21;5(10): - PubMed
  19. Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18754-9 - PubMed
  20. Mol Genet Metab. 2004 Apr;81 Suppl 1:S79-85 - PubMed
  21. J Immunol. 2007 Jul 1;179(1):275-83 - PubMed
  22. Mol Brain. 2012 May 14;5:14 - PubMed
  23. J Inherit Metab Dis. 2007 Nov;30(6):865-79 - PubMed
  24. Gastroenterol Hepatol (N Y). 2013 Apr;9(4):219-27 - PubMed
  25. Biochim Biophys Acta. 2008 Jan;1784(1):16-26 - PubMed
  26. J Immunol. 2012 Jul 15;189(2):1002-13 - PubMed
  27. PLoS One. 2015 Jun 23;10(6):e0130398 - PubMed
  28. Semin Neonatol. 2002 Feb;7(1):27-35 - PubMed
  29. J Biol Chem. 2012 Aug 3;287(32):27189-203 - PubMed
  30. J Biol Chem. 2012 Aug 24;287(35):29529-42 - PubMed
  31. Neuron. 2003 Sep 11;39(6):889-909 - PubMed
  32. J Clin Cell Immunol. 2013 Aug 12;7:158 - PubMed
  33. Annu Rev Neurosci. 1999;22:123-44 - PubMed
  34. J Immunol. 2009 Apr 15;182(8):5013-23 - PubMed

Publication Types